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Gene expression programmes driving cell identity are established by
tightly regulated transcription factors that auto- and cross-regulate in a
feed-forward manner, forming core regulatory circuitries (CRCs). CRC tran-
scription factors create and engage super-enhancers by recruiting acetylation
writers depositing permissive H3K27ac chromatin marks. These super-
enhancers are largely associated with BET proteins, including BRD4, that
influence higher-order chromatin structure. The orchestration of these
events triggers accessibility of RNA polymerase machinery and the impo-
sition of lineage-specific gene expression. In cancers, CRCs drive cell
identity by superimposing developmental programmes on a background
of genetic alterations. Further, the establishment and maintenance of onco-
genic states are reliant on CRCs that drive factors involved in tumour
development. Hence, the molecular dissection of CRC components driving
cell identity and cancer state can contribute to elucidating mechanisms of
diversion from pre-determined developmental programmes and highlight
cancer dependencies. These insights can provide valuable opportunities
for identifying and re-purposing drug targets. In this article, we review
the current understanding of CRCs across solid and liquid malignancies
and avenues of investigation for drug development efforts. We also review
techniques used to understand CRCs and elaborate the indication of dis-
cussed CRC transcription factors in the wider context of cancer CRC models.1. Introduction
Programmes involved in the control of gene expression governing cell state, cell
state transitions and cellular identity across cell types or lineages have not been
comprehensively defined. However, multiple efforts encompassing a myriad of
differentiation models have shed light on the mechanisms regulating these
developmental programmes [1–5]. These programmes are controlled by a
small set of tightly regulated transcription factors (TFs) and/or de novo fusion
chimeric TFs, forming core regulatory circuitries (CRCs). These CRCs control




2these core regulatory TFs (CR TFs) can control the placement
of acetylation deposits around an array of CR TF binding
motifs by recruiting acetylation writers, readers and erasers,
thereby creating super-enhancers (SEs) [9]. SEs are broad,
spatially co-localized enhancer regions that recruit dense
transcriptional machinery. SEs are disproportionately larger
than most enhancer domains and contain close to 40% of
enhancer-associated factors (including epigenetic machinery),
while comprising only 3–5% of enhancer regions [10]. CR TFs
drive cell identity by binding to SEs associated with lineage
identity imposing genes, often oncogenes [6,8,10–12]. CR
TFs self-regulate and, they inwardly bind to their own regu-
latory regions and mutually regulate within the CRC,
forming a cross-regulated feed-forward loop [6]. Research
efforts to date have focused on understanding components
of CRCs and their roles in multiple cell types, including
embryonic stem cells (ESCs), induced pluripotent stem cells
(iPSCs) and multiple cancer cell types [13–15]. In ESCs,
CRC TFs including OCT4, SOX2 and NANOG regulate them-
selves and each other [10,14]. These CRC TFs dominate the
transcriptional programmes governing stem cell self-renewal,
pluripotency and cell fate [10,14]. Expression of this network
of CRC TFs, with the addition of the proto-oncogene C-MYC,
was sufficient to reprogramme somatic cells into iPSCs [16].
Similar efforts in cancers have brought into focus tumour
dependencies and regulatory diversity and, in some cases,
addiction to regulatory circuitries [15]. Further, SEs, as com-
ponents of CRCs, are linked to regions of somatic genetic
alterations such as focal amplifications in cancers and disease
linked-SNPs [17,18]. SEs can also reinforce the expression of
factors indicated in tumour development and progression
[11].
An important step in understanding the role of CRCs in
cancers is the systematic reconstruction of CRCs both in
development and cancer. The reconstruction of CRCs for a
cell type requires SE maps (usually indicated by high levels
of a H3K27ac histone signature), core TF binding data, their
putative binding sites in the SE regions and their extended,
genome-wide, regulatory network [6,19]. To that end, Saint-
André and colleagues reconstructed and predicted CRC
models using a CRC mapper programme for 75 human cell
and tissue types [6]. Huang and colleagues developed a
dbCoRC database which, in addition to archiving CRC infor-
mation, interactively reconstructs CRCs for over 230 human
and mouse cell lines or primary tissue, inclusive of 79
cancer cells and tissues [19]. This database provides cell-
type specific information about SEs, CRC models, putative
binding sites for TFs identified in target gene SEs, and TF
expression patterns [19]. Other resources such as dbSUPER
also provide a comprehensive map of SEs identified in
more than 100 cell types, which may be used to complement
CRC model data [20]. The next step beyond CRC reconstruc-
tion in cancers is understanding the cellular and molecular
mechanisms of divergence of constitutive developmental pro-
grammes in a background of genetic aberrations [6]. The
inference of the underlying transcriptional networks that
regulate physiological and pathological states is likely to
inform these mechanisms of diversion and enhance our
understanding of both physiology and disease. Put together,
it is reasonable to propose that understanding the role
of CRCs in cancers will facilitate the dissection of identity-
conferring programmes and lead to a better understanding
of their deregulation in cancers, potentially informing drugdevelopment and re-purposing strategies [15,21,22]. In this
article, we review the present knowledge of CRCs across a
multitude of solid and liquid cancers, and the current evi-
dence for leveraging this information for therapeutic gain.
We then attempt to elaborate the indication of discussed
CRC TFs, in a wider range of cancer cells and tissues
using the dbCoRC database. Finally, we describe current
methodologies used to understand CRCs.2. CRCs in a multitude of solid and liquid
cancer types
In this section, we address the role of CRCs in controlling the
flow of information that governs identity-conferring pro-
grammes in a multitude of solid and liquid cancer types
(figure 1).
2.1. Neuroblastoma
Neuroblastoma (NB) is a solid malignancy derived from mul-
tipotent neural crest cells (NCCs) and contributes to 15% of
cancer-related mortality in children [23]. Recent studies
have defined the presence of two interconvertible types of
NBs regulated by CRCs; committed adrenergic (ADRN)
and neural crest migratory (or mesenchymal; MES) [12,24].
Though both cell populations are oncogenic [24], the latter
type displays greater therapeutic resistance and encompasses
the majority of relapsed tumours [25].
The Notch signalling pathway is the driver of motile MES
identity, consistent with a mesenchymal phenotype. MES
CRCs include the NOTCH receptors and cofactors,
NOTCH2 and MAML2, respectively, which are associated
with SEs and drive an array of NOTCH target genes includ-
ing HES1 [24,26,27]. Members of the CRC-regulating MES
state, namely, the NOTCH family, NOTCH1, NOTCH2 and
NOTCH3, can initiate transdifferentiation to the ADRN
state through H3K27ac landscape remodelling [24] and
hence control maintenance of the MES state. However, the
intracellular domain of NOTCH3 is the strongest inducer of
reprogramming towards the MES state. Induction of the
NOTCH3 intracellular domain leads to de novo establishment
of SEs at NOTCH2 and MAML2 loci as well as the deposition
of H3K27ac at the promoter regions of JAG1, NOTCH1,
NOTCH3 and HES1 [24].
The CRC regulating the ADRN subtype in NB comprises
PHOX2B, HAND2, TBX2, ISL1, ASCL1 and GATA3, whose
effects are amplified by MYCN and LMO1 [25,28–30]. The
most recent addition to this circuitry, ASCL1, a bHLH
transcription factor implicated in NB cell growth and
differentiation arrest, is directly regulated by LMO1, MYCN
and other members of the CRC [31]. Similarly, ASCL1
directly regulates the expression of other genes in this CRC,
forming an auto-regulatory loop [31]. Other members of
this CRC, including GATA3, a biomarker linked to the
proliferation of NB cells and self-renewal capacity [32], is
downregulated following retinoic acid (RA) treatment,
inhibiting tumourigenicity [32,33]. In addition, ISL1 posi-
tively regulates cell cycle genes and represses genes
associated with differentiation (e.g. RA receptors, CDKN1A
and EPAS1) [34].
The events leading to the oncogenic capacity and speci-




























Figure 1. Core regulatory circuitry (CRC) constitutes a network that can confer lineage-specific gene expression. Core regulatory transcription factors (CR TFs) self-
regulate and regulate the expression of other CR TFs in a cross-regulated feed-forward loop. Super-enhancers (SEs) contain CR TF binding sites and marked H3K27ac
deposits. CR TFs, in turn, bind to the regulatory regions of a network of target genes (TGs) including lineage-specific genes that drive cell identity. TF, transcription






development are still unknown. However, recent work by
Soldatov and colleagues, which profiled gene expression
during mouse neural crest development, may provide
insights into the timing of NB oncogenesis. Single-cell RNA
sequencing identified a novel bipotent cell type, a dual fate
progenitor expressing both Phox2b and Prrx1, late in the
differentiation cascade of NCCs [35]. As discussed,
PHOX2B is expressed in ADRN subtypes while PRRX1 is
MES-specific, and its overexpression is sufficient to convert
ADRN to MES subtypes [24,25]. The existence of these dual
progenitors could indicate they are upstream of the oncogenic
event leading to the formation of both MES and ADRN NBs,
and that further characterization of the complex SEs regulat-
ing cell fate decisions at this stage will be likely to inform NB
biology. Table 1 summarizes examples of CRC TFs discussed
in this section.
2.2. Glioblastoma
Glioblastoma (GBM) is the most common primary malignant
brain tumour in adults and harbours distinct heterogeneous
populations of tumour cells [43]. Earlier studies identified
CRCs comprising the POU3F2, SOX2 and SALL2, OLIG2
TFs whose activities reprogrammed differentiated GBM
cells into induced tumour propagating cells (TPCs). These
TPCs have stem-like properties, are capable of tumourigen-
esis and display unique SE landscapes [43–45]. A target
gene of this network is RCOR2, which forms a protein com-
plex with LSD1, a histone methyltransferase. The RCOR2/
LSD1 complex replaces OLIG2 in the reprogramming cocktail
towards TPC [44]. Notably, most of these genes are involved
in the maintenance of neural stem cell (NSC) identity during
development. Expression of Pou3f2 (Brn2) was shown to be
sufficient to convert astrocytes into neural progenitors in
mice, similar to its role in the formation of TPCs [46]; SOX2
and OLIG2 are involved in maintaining the identity and
replication potential of neural progenitors [47,48].In a study conducted on glioblastoma stem cells (GSCs),
NOTCH1, SOX2, SALL2, POU3F and OLIG2 blocked differ-
entiation in GSCs, confirming the observations made in
GBM by Suvà and colleagues [44,45]. Although the simi-
larities and differences between induced TPCs and GSCs is
not clear, it may be possible to propose that cells with self-
renewal and tumourigenesis capacity can be identified in
GBM or induced from differentiated GBM. Building on
these observations, in a more recent study, Riddick and col-
leagues compare the global gene expression pattern of
GSCs and NSCs during in vitro differentiation [36]. This
group revealed a substantial overlap between the regulatory
landscape of GSCs and NSCs. Further, in addition to the
identification of important transcriptional regulators of GSC
and NSC biology, such as SOX2, OLIG2, DLL, NOTCH and
HES1, there were other significant observations. First, GSCs
akin to NSCs express SOX2, Nestin and CD133, and demon-
strate self-renewal and multi-potency while sharing common
yet deregulated developmental pathways with NSCs includ-
ing AKT, RAS, NOTCH, BMI-1 and WNT [36,49–53]. Second,
the binding signature of TFs to differentially expressed genes
was used to reconstruct a CRC centred on KLF4, a TF
involved in activation of DDL1, NOTCH1 and SOX2 [36].
The overexpression of KLF4 in both GSCs and NSCs blocks
differentiation and reduces proliferation [36,54]. In GSCs,
KLF4 is regulated by ERG1 and sits downstream of STAT3
in the PI3K pathway [36].
Finally, consistent with potential plasticity of cell identity,
glioblastomas can be reprogrammed towards mesenchymal
lineages by the synergistic activity of initiators and master
regulators, including STAT3 (downstream of PI3K activity)
and CEBPB. Ectopic expression of these genes in NSCs repro-
grammes these cells towards the mesenchymal lineages, and
their expression in tumours is predictive of poor clinical out-
comes, consistent with promoting motile phenotypes in
these cells [55]. Table 1 summarizes examples of CRC TFs
discussed in this section.
Table 1. Summary data of relevant CRC TFs identified in the indicated malignancies. In this table, cancer type and examples of subtype, subgroups, cliques or
modules identified have been summarized. Further examples of CRC TF identified in each subtype, group, module or clique have been provided.
cancer
subtypes, subgroups or
identified modules examples of identified CRC TFs
neuroblastoma [24,31] MES NOTCH receptors and cofactors including NOTCH2 and MAML2
ADRN PHOX2B, HAND2, TBX2, ISL1, ASCL1 and GATA3, MYCN and LMO1
glioblastoma [36] KLF4, ERG1, Notch pathway and SOX2
rhabdomyosarcoma [9] Pan-RMS MYOD1 and MYOG
FP-RMS PAX3-FOXO1, MYCN, SOX8, MYOD1 and MYOG
fusion–negative RMS PAX7 and AP1 family
normal muscle-specific (NMS) Nur77 and MEF2D
renal cell carcinoma [37] PAX8
liposarcoma [38] myxoid (MLPS) FUS-DDIT3
de-differentiated (DDLPS) FOSL2, MYC and RUNX1
prostate cancer [39] AR and ERG
gastrointestinal stromal tumour (GIST) [40] FOXF1 and ETV1
medullablastoma [21] group 3 HLX and LHX2
group 4 LMX1A and LHX2
chronic lymphocytic leukaemia (CLL) [41] CLL-2 (clique 2) PAX5, ETV6, TCF3, IRF2, MEF2D, ELF1, KLF13, JUND, FOXP1,
IRF1 and IRF8
CLL-11 (clique 11) PAX5, ETV6, TCF12, IRF2, RARA, NFATC1, KLF12, JUN, RUNX3
and FLI1






Childhood rhabdomyosarcoma (RMS) is the most common
soft tissue sarcoma in paediatric patients [56]. RMS oncogen-
esis relies on the expression of myogenic TFs [57], generating
at least four identified CRCs in RMS tissue and cell lines: (i) a
pan-RMS CRC defined by expression of MYOD1 and MYOG;
(ii) a fusion-positive RMS (FP-RMS), which includes FOXO1
(SEs regulating PAX3-FOXO1 or PAX7-FOXO1) and
MYCN; (iii) a fusion-negative RMS including PAX7 and the
AP1 family of TFs; and (iv) a normal muscle-specific CRC
with TFs expressing Nur77 and MEF2D [58,59].
The FP-RMS module is formed by a t(2:13)(q35:q14) trans-
location forming a PAX3-FOXO1 fusion gene, which
functions as a primary oncogenic driver [9]. A consistently
high-scoring H3K27ac signal and open chromatin structure
was identified in the SE regions of SOX8 in primary FP-
RMS samples. More detailed investigation revealed that
PAX3-FOXO1 positively regulates MYOD1, MOYG and
SOX8 in a feed-forward mechanism [9].
MYOD1 and MYOG lead a pro-myogenic programme in
RMS, while SOX8, a regulator of early neural crest develop-
ment, displays anti-myogenic functions and opposes the
ability of these factors to complete muscle differentiation
[60]. Crucially, it is through the binding of PAX3-FOXO1
to SEs of SOX8 and subsequent activation of SOX8
expression that this fusion protein can exert its anti-
differentiation activity on these cells [9]. In conclusion,
MYOD1 and MYOG are drivers of the myogenic pro-
gramme, which is opposed by PAX3-FOXO1 via binding
to the SE of SOX8.The transcriptional interaction between SOX8, MYOD1
and MYOG is also interesting. Disruption of either MYOD1
or MYOG results in dramatic transcriptional downregulation
of MYOD1, MYOG, SOX8 and other TFs. Conversely, SOX8
is highly overexpressed in FP-RMS tumours, and SOX8
disruption leads to upregulation of MYOD1 and MYOG in
FP-RMS, suggesting a negative regulatory mechanism [9].
In conclusion, the FP-RMS CRC model includes feed forward
(PAX3-FOXO1 and MYOD1, MYOG and other TFs) and
negative feedback (SOX8) mechanisms [9,61].
In a more recent publication, Gryder and colleagues
further dissect the CRC of FP-RMS and put forth a detailed
mechanistic view of the chromosomal translocation that
leads to hijacking of the PAX3 promoter by FOXO1 SE [62].
This group demonstrates that the SE of FOXO1 interacts
with smaller intergenic and intronic enhancers of FOXO1
and PAX3 promoter. In the stepwise developmental pro-
gramme of skeletal muscle, PAX3 activates MYOD1
through MYOD1 SE, but MYOD1 does not upregulate
PAX3, and wild-type PAX3 enhancers are silent while
MYOD1 and MYOG promote differentiation in late myogen-
esis [62]. By contrast, upon FOXO1 SE translocation to
regulate PAX3 in FP-RMS, MYOD1, MYOG and MYCN can
also bind to and drive this SE. This leads to the continuous
expression of PAX3-FOXO1 in late stages of myogenesis
and halting of FP-RMS tumours in an undifferentiated
state. These newly formed ‘miswired’ enhancer elements
fuel the pathological diversion from normal skeletal muscle
development in FP-RMS [62]. Table 1 summarizes examples




52.4. Renal cell carcinoma
Renal cell carcinoma (RCC) is a heterogeneous cancer
accounting for 2% of all cancer cases [63]. Clear cell RCC
(ccRCC) is the most common subtype of this disease (greater
than 80% of all cases) and the main cause of RCC mortality.
ccRCC harbours truncal mutations in the VHL gene (von
Hippel-Lidau tumour suppressor) implicated in activation
of TFs such as HIF1α and HIF2α that are involved in angio-
genesis, metabolism and cell death [64]. However,
consistent with the Knudsen’s two-hit genetic alteration
hypothesis, the addition of a second genetic alteration in
mTOR pathways or chromatin modifiers is also required for
induction of ccRCC [65]. In a recent study, PAX8, a cell-auton-
omous transcriptional activator, was identified as a potential
CRC oncogenic driver in RCC, which may be independent of
VHL alteration status [37]. PAX8 knockdown in an array of
RCC cell lines revealed a network of over 460 genes including
those involved in metabolism, kidney cell fate, proliferation
and the process of tumourigenesis (e.g. kidney-specific cad-
herins, claudins and cell cycle genes) under PAX8
regulation. One key difference between PAX8 regulation of
metabolic genes compared with its other targets was the
prevalence of H3K27ac. Specifically, cell cycle and metabolic
pathway genes gained H3K27ac marks indicating that they
were enhancer-regulated by PAX8, rather than promoter-
regulated [37]. An example of a PAX8 target gene (and also
HIF) is ferroxidase ceruloplasmin (CP), implicated in the
iron-metabolic pathway in RCC tumourigenesis [37]. CP is
also a marker of refractory disease and low survival in RCC
patients in addition to being a predictor of PAX8 activity
[37]. Table 1 summarizes examples of CRC TFs discussed
in this section.
2.5. Liposarcoma
Liposarcomas (LPSs), or soft tissue sarcomas, aremesenchymal
tumours that account for 20% of adult sarcomas [66]. Somatic
abnormalities in LPS tumours comprise overexpression of
CDK4 and MDM2, and 12q13–15 amplification [67]. Four LPS
subtypes have been identified; well-differentiated (WDLPS),
myxoid (MLPS), pleomorphic (PLPS) and de-differentiated
(DDLPS), the latter three comprising most high-grade
cases; PLPS and DDLPS mainly lead to disease relapse
post-treatment, while MLPS displays better prognosis [68].
Charting H3K27ac modifications of LPS (DDLPS and
MLPS) cell lines and primary tissue, mesenchymal stem
cells and mature adipocytes, revealed that some SEs are
retained from the adipogenesis programme (e.g. FOSL2). By
contrast, SEs of definitive adipocyte genes are ablated (e.g.
CEBPA and PPARG) while there is de novo establishment of
SEs related to genes associated with transformation (e.g.
MYC, CDK6 and JUN) [38]. In these LPS samples, the SEs pre-
ferentially used are those associated with tumourigenesis,
including cell migration, angiogenesis and other develop-
mental processes [38]. Finally, a low-to-moderate overlap
was observed between DDLPS and MLPS SEs in primary
tissue and cell lines [38].
The defining factor in the MLPS CRC is a fusion oncogene
resulting from the t(12;16)(q13;p11) translocation, forming a
hallmark MLPS FUS-DDIT3 fusion which functions as a TF
[69,70]. FUS-DDIT3 is disproportionately distributed in the
genome, especially in SE regions contributing to deregulatedgene expression and an aberrant epigenetic landscape. One
interesting observation in this subtype was transcriptional
addiction owing to preferential SE association with genes reg-
ulating RNA-Pol2 activity. Consistent with this, close to 9% of
FUS-DDIT3 bound to promoters with high RNA-Pol2 activity
[38]. When present, a double H3K27ac and FUS-DDIT3 mark
led to high basal expression levels (e.g. FST and IL8), display-
ing its potential for corruption of epigenetic landscapes. A
known group of interactors with histone acetylation marks
of SE regions are bromodomain and extra terminal domain
proteins (BET) [71]. Consistent with the notion that oncogenic
fusion TFs hijack BET proteins to activate malignant trans-
formation, substantial co-localization and co-operation
between FUS-DDIT3 and the BET protein BRD4 has been
detected in MLPS [11,38]
CRCs associated with DDLPS comprise FOSL2, MYC and
RUNX1, whose maintenance is dependent on BET proteins.
Marked co-occupancy of RUNX1 and FOSL2 activates a net-
work of targets involved in the pathogenesis of liposarcoma
and malignant growth [38]. Specifically, FOSL2 and RUNX1
proteins co-occupy the SE regions of all described CRC TFs
in this LPS subtype. These genes collectively maintain the
expression of SNAI2, indicated in EMT and proliferative
capacity, and a potential prognostic marker for this subtype.
Higher SNAI2 is also linked to shorter disease-free survival
(DFS) in DDLPS patients [38]. Finally, demonstrating the
dependency of the DDPLS CRC on BRD4, depletion of
BRD4 attenuated distant metastasis [38]. Table 1 summarizes
examples of CRC TFs discussed in this section.
2.6. Prostate cancer
Prostate cancer is one of the major causes of cancer-related
deaths in men [72]. The androgen receptor (AR) dictates the
transcriptional output that promotes proliferation and survi-
val of prostate cancer cells. Studies focused on dissecting the
mechanisms of AR-centred prostate cancer development
reveal that AR not only regulates gene expression but also
regulates higher-order chromatin configuration [73]. More
specifically, a study [39] identified that 55% of AR binding
sites function as anchors that mediate duplex and complex
AR-associated chromatin interactions (ARanchor), while the
remaining 45% did not participate in chromatin interaction
(ARalone). There was a two-fold enrichment of androgen
upregulated genes in ARanchor regions compared with
ARalone regions, which highlights that long-range chromatin
looping may be pivotal to AR regulatory functions [39].
TFs can interact with nuclear hormone receptors such as
the AR to govern different aspects of transcription and chro-
matin regulation [74]. A recurrent fusion gene in prostate
cancers, ERG (erythroblast transformation-specific related
gene), was shown to interact and collaborate with AR through
chromatin looping [73,74]. The ERG interactome, including
ERG-associated long-range chromatin, is a collaborative com-
ponent of higher-order AR-associated chromatin structure
and is involved in co-regulating subtypes of AR target genes
in prostate cancer. For instance, this study detected inter-
twined ERG-associated and AR-associated chromatin loops
in relation to genes or gene clusters such as FKBP5, VCL,
KLK family, EAF2 and SLC15A2-ILDR1 [39].
AR and ERG co-bind to regulatory sites associated with
long-range chromatin interactions (AR+ERG+anchor). These




6TF binding motifs and bi-directional transcription [39].
Further, these AR and ERG-associated highly connected
hubs co-localized with sites for binding of epigenetic regula-
tors/histone remodelling factors and lncRNAs [39]. With
regard to co-localization of epigenetic regulators/histone
remodelling factors with distinct AR-ERG transcriptional
network, three distinct genomic signatures were identified:
(i) FOXA1, EZH2 and HDAC3 that are enriched with
AR+ERG+anchor sites; (ii) HDAC1, BRD2, BRD3 and BRD4
that are enriched with AR-ERG+anchor and AR
-ERG+alone (ERG
in the absence of AR); and (iii) POLR2A, HDAC2 and
GAPBPA that are enriched with AR looping but not
AR+ERG+alone and AR
+ERG-alone [39].
With respect to IncRNAs, one potential function of AR
and ERG chromatin looping may be to allow interactions
between lncRNA and its target gene. For instance, manipulat-
ing three lncRNAs identified in association with the PMEPA1
locus (PCAT43, PCAT61 and PCAT76) led to a reduction in
androgen-triggered expression of the gene [39]. One other
example of the clinical relevance of AR and ERG chromatin
loops is the link detected between a prostate cancer GWAS
SNP, rs9364554, located in the intron of SLC22A3 within an
AR and ERG loop anchor. This loop also connects this SNP
with SLC22A2 in the vicinity [39]. Table 1 summarizes
examples of CRC TFs discussed in this section.2.7. Gastrointestinal stromal tumour
Gastrointestinal stromal tumour (GIST) is a common soft
tissue sarcoma, originating from interstitial cells of Cajal
(ICC) [75]. The ICC lineage is reliant on KIT and ETV1 for
specification and survival, whereby KIT and ETV1 function
as signalling and lineage-specific regulators, respectively
[75,76]. During development, the transcriptional input
required for ICC lineage specification constitutes KIT acti-
vation by KIT ligand and consequent MAPK-mediated
stabilization of ETV1 protein, establishing lineage specifica-
tion [75]. In the pathological context, mutant KIT stabilizes
ETV1 (through aberrant MAPK signalling activation), while
in turn, ETV1 promotes mutant KIT expression, forming a
divergent positive feedback loop fuelling the process of
tumourigenesis [40].
FOXF1, a member of the fork-head family of transcription
factors, is specifically expressed in GIST and directly regu-
lates the transcription of KIT and ETV1. In turn, FOXF1 and
ETV1 both regulate KIT, although FOXF1 regulation of KIT
is significantly stronger owing to the regulation of both chro-
matin accessibility and the ETV1 cistrome [40]. This evidence
may support the pre-existence of this regulatory pattern
between KIT and FOXF1 in non-oncogenic ICC develop-
ment, highlighting similarities between physiological and
pathological development.
FOXF1 also co-localizes with ETV1 to regulate ICC/GIST
lineage-specific gene expression by maintaining open chro-
matin structure and enhancers, as well as the recruitment of
ETV1 to lineage-specific enhancers. Examples of ETV1-
dependent ICC/GIST lineage-specific gene networks
regulated by FOXF1 include DUSP6, GPR20 and ANO1 [40].
With respect to FOXF1 regulation, KIT or MAPK pathway
perturbations do not significantly affect the expression of
FOXF1, placing it at the top of a regulatory hierarchy for
GIST. Finally, FOXF1 is required for GIST cell cycleprogression, tumour growth and maintenance [40]. Table 1
summarizes examples of CRC TFs discussed in this section.
2.8. Medulloblastoma
Medulloblastoma, a malignant paediatric brain tumour aris-
ing from the cerebellum, medulla and brain stem, is
categorized into four clinically and biologically distinct sub-
groups [77]. These four core subgroups, WNT, SHH, group
3 and group 4, are classified based on their inherent differen-
tial and discriminatory transcriptional profiles. The WNT and
SHH subgroups are named based on the activity of the
respective pathways, and groups 3 and 4 display regulatory
similarities [78] but present diverse phenotypes and express
GABAergic and glutaminergic cell-type characteristics,
respectively [21,77]. In addition to somatic alterations in
driver genes such as MYC (group 3), KDM6A (group 4)
and GFI1/ GFI1B (group 3 and 4) [21,77,79], epigenetic modu-
lation may influence transcriptional programming specific to
subgroups [80].
The computational reconstruction of SE and enhancer
mapping for 28 medulloblastoma primary tissue has been
used to dissect differential group 3 and 4 CRCs [21]. This
mapping approach identified large SEs associated with cer-
ebellum-specific TFs, ZIC1 and ZIC4, and SEs associated
with medulloblastoma driver genes and epigenetic modu-
lators, such as GLI2, MYC and OTX2 [21]. On a subgroup
level, SEs were then inferred to regulate ALK in the WNT
group, SMO and NTRK3 in the SHH group, LMO1, LMO2
and MYC in group 3, and ETV4 and PAX5 in group 4 [21].
This group-specific SE allocation was based on an unbiased
hierarchical clustering strategy of SEs across the samples ana-
lysed. One key observation in the study was that SE patterns
observed differed substantially between medulloblastoma
primary tissue or cell lines highlighting regulatory and
CRC component dissimilarities [21]. This study also ident-
ified core TFs implicated in establishing medulloblastoma
group identity including HLX (group 3), LMX1A (group 4)
and LHX2 (shared between groups 3 and 4), providing
some evidence towards the cell-of-origin of these disease
groups [21]. In terms of functional pathway enrichment,
TGFβ signalling and neuronal transcriptional regulators
were enriched in groups 3 and 4, respectively [21]. Table 1
summarizes examples of CRC TFs discussed in this section.
2.9. Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is a highly hetero-
geneous B-cell haematological malignancy with low cure
rates. A spectrum of genomic alterations in this malignancy
have been identified, including segmental chromosomal
alterations, copy number alterations and somatic nucleotide
alterations, while 13q deletion is the most recurrent alteration
[81,82]. The CLL-specific CRC is centred on PAX5, a TF that
promotes lymphomagenesis by activating signalling path-
ways indicated in B-cell signalling, and the knockdown of
this gene results in dramatic effects on B-cell proliferation
and development [41,83].
In a study aimed at dissecting CRCs in primary CLL and
normal B cells (NBCs), SEs with exceptionally high H3K27ac
marks (42% of all H3K27ac marks globally) were discovered
in proximity to genes involved in CLL pathobiology, includ-




7high proportion of H3K27ac at these few loci of total global
H3K27ac activity concomitant with open chromatin structure
(tested by ATAC-seq) demonstrates the dominance of these
SEs in regulating transcriptional output. For instance, the
SE of the BCL2 gene that is usually upregulated in CLL,
open chromatin structure and broad H3K27ac signals were
detected [41]. The SE of CTLA4, encoding a T-cell inhibitory
checkpoint effector, also displayed strong H3K27ac signals.
The NBC samples used in this study showed 230 SEs, includ-
ing SEs proximal to BACH2 and BANK1, known to play roles
in lymphoma suppression [41,84]. Further, despite samples
displaying substantial heterogeneity, a core of large SEs dis-
played regulatory conservation among a subset of the CLL
patient samples in loci pertinent to KRAS, CD5, PAX5,
CXCR4, BCL2 and CD74 [41]. Finally, this study defines an
enhancer-based CRC analysis system. Specifically, for TFs
associated with top-ranked enhancers, inward TF enhancer
binding by other TFs and outward binding of the TF of inter-
est to their extended enhancer network were assessed. This
information was processed to describe ‘cliques’ of auto-regu-
latory TFs [41]. At least four representative cliques were
defined: CLL-2, CLL-3, CLL-8 and CLL-11. For instance,
TFs constituting the CLL-2 clique include PAX5, ETV6,
TCF3, IRF2, MEF2D, ELF1, KLF13, JUND, FOXP1, IRF1
and IRF8 [41]. Highly connected CLL and NBC TFs across
samples comprised PAX5 and the IRF family in addition to
FOXP1, RARA and ETS1 [41]. Table 1 summarizes examples
of CRC TFs discussed in this section.
2.10. T-cell acute lymphoblastic leukaemia
For T-cell acute lymphoblastic leukaemia (T-ALL), malignant
transformation gives rise to leukaemic cells owing to deregu-
lated thymic differentiation programmes [85]. The oncogenic
TF, TAL1, is crucially involved in the pathogenesis of T-ALL
cases and has been shown to collaborate with other TFs to
form a CRC. This CRC comprises TAL1, HEB, E2A,
LMO1/2, GATA3 and RUNX1 in T-ALL representative cell
lines, such as Jurkat and CCRF-CEM [42]. A high coincidence
of genomic site occupation was observed in this study
between TAL1 and other CRC TFs including LMO1/2,
GATA3 and RUNX1. In these two cell lines, three different
classes of regulatory elements were identified: group 1 (con-
cordant enrichment for TAL1 complexes), group 2 (mainly
GATA3 occupation) and group 3 (mainly RUNX1 occu-
pation). In terms of the presence of identified binding
motifs, these were, for group 1, E-box, GATA, RUNX and
ETS, for group 2 GATA and ETS motifs, and for group 3
RUNX, ETS and SP1 [42].
In summary, TAL1 forms an auto-regulatory loop with
GATA3 and RUNX1, and they occupy regulatory regions of
their own and each other’s genes. TAL1 initiates this auto-
regulatory loop, and the sustained upregulation of GATA3
and RUNX1 by TAL1 may contribute to reinforcement of
the malignant programme in T-ALL [42]. Further, TAL1 posi-
tively regulates the expression of a network of target genes in
collaboration with GATA3 and RUNX1 [42].
Target genes of TAL1 include TRIB2 and MYB whereby
the former regulates cell survival in TAL1-positive T-ALL
cells, while the latter is a transcriptional regulator driving
normal and malignant blood haematopoiesis [86]. MYB is
induced by TAL1 and in turn, MYB co-regulates a subset of
TAL1 target genes, stabilizes and reinforces the TAL1oncogenic programme [42]. One example for collaboration
between TAL1 and MYB in TAL1-positive T-ALL cells is
that the enhancer region of TAL1 can be targeted by numer-
ous somatic alterations which then form new MYB binding
sites and SEs, effectively extending the outreach of MYB
[18]. An example of negative and positive regulation in
T-ALL is the TAL1, HEB and H2A regulatory network.
TAL1, HEB and H2A coordinately regulate target genes. Of
these target genes, a subset is directly activated by TAL1
but repressed by HEB and H2A [42]. Table 1 summarizes
examples of CRC TFs discussed in this section.3. CRCs and drug development
The dissection of regulatory networks associated with cell
identity in cancer facilitates a better understanding of the
malignancy and the identification of appropriate treatment
strategies. CRCs provide a framework for the identification
and potential targeting of oncogenic CRC TFs, transcriptional
co-activators, SEs and SE-associated co-activators and modu-
lators as justifiable avenues of targeting. One example of
targeting master regulator TFs for therapeutic gain is in
GIST. This cancer is highly resistant to standard chemother-
apy, and is instead sensitive to specific targeting of KIT and
ETV1 lineage-specific CRC TFs [87,88]. Further, CRC TFs
recruit acetylation writers such as CBP/p300, readers such
as BRD4 and erasers such as HDACs and other factors to con-
struct SEs [8,22]. BRD4 and related proteins have been shown
to occupy large numbers of enhancers, especially SEs [11,15].
Due to this association, SEs may be sensitive to drugs that
target BET domain regulators and kinases involved in tran-
scription [15,89]. Despite the broad presence of BET
proteins across thousands of enhancers, inhibition of these
proteins (for instance the inhibition of BRD4 by the BET-bro-
modomain inhibitor JQ1), has led to specific targeting in
multiple cancers, revealing cancer dependencies. In multiple
myeloma, JQ1 treatment led to specific MYC inhibition [15]
(figure 2), while in CLL, BET inhibition led to the downregu-
lation of multiple survival pathways involved in CLL biology
[90]. This pattern was also observed in diffuse large B-cell
lymphoma (DLBCL), in which SEs of oncogenic and line-
age-specific CRCs showed particular sensitivity to BET
inhibition [11].
In addition to gene or gene network targeting, BET
protein inhibition may be explored to sensitize cases of
relapse and treatment resistance. For instance, in solid
tumours such as LPS, targeting BET proteins using ARV-
825, a BET protein degrader, can provide advantages in over-
coming trabectedin resistance [38]. In terms of cellular effects,
BET protein inhibition and depletion mainly triggers apopto-
sis or cytotoxic effects in cancers, including osteosarcomas
and breast cancer [91,92].
One other outcome of chemical targeting of SEs is to
understand SE driven transcriptional addiction in cancers.
In multiple myeloma, JQ1 treatment more dramatically
affects SEs and SE-associated genes compared with typical
enhancer-associated genes [15]. Cancer addiction to CR tran-
scription has been described in RMS, in which the PAX3-
FOXO1 fusion protein activates SEs to activate the expression
of other CR TFs in a feed-forward manner, leading to high
levels of CR TF expression [22]. Consistent with transcrip-
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Figure 2. BET inhibitor treatment represses transcription of super enhancer-associated transcription factors. BET proteins (including BRD4) regulate chromatin and
RNA polymerase accessibility to the gene of interest. BET inhibitors such as JQ1 can induce disruption of SEs and specific transcription elongation defects and





was achieved by targeting the acetylation axis in this cancer
[22]. Specifically, this study showed that co-inhibition of
HDAC1, HDAC2 and HDAC3 halts CR transcription by
interfering with chromatin accessibility and looping [22]. In
conclusion, understanding the dependency and mechanistic
connections between BET proteins and deregulated pro-
grammes and enhancer states can provide avenues for
target identification and therapeutic gain.4. Similarities between CRC models in the
wider context of human cancer
The CRC TFs identified in this study, although displaying
specific functions in each cancer’s CRC, may indeed be
involved in gene regulatory networks in a spectrum of
other human cancer cell lines and primary tissues. The
dbCoRC database permits the collation of information con-
cerning cell or tissue expression of a given CRC TF,
upstream and downstream targets of this TF within the
CRC model, SE genomic coordinates and the number of TF
binding sites within the SE of the targets (CRC TFs) [19].
Here, we have used this tool to further study the CRC TFs
indicated in the 10 cancer types discussed in this review in
other cell lines. Table 2 outlines reviewed CRC TFs indicated
in other human cell lines and primary tissue, and the CRC
model formed. For instance, FOXP1 and ERG reviewed in
the context of CLL and prostate cancers, respectively, are
both indicated in the CRC model of a colorectal cancer cell
line, COLO320 (ASCL2, DBP, ERG, FOXG1, FOXP1, MEIS1,
OSR1, SOX5, SP1, TBX2, TEAD1, TFAP2C and TFAP4).
Another example is GATA3, which has been reviewed in
this article in NB and T-ALL, and has also been identified
in the regulatory networks of a breast cancer cell line (ZR-
75-1) [19,31,42]. This regulatory network comprises TFs
such as: EHF, FOXA1, GATA3, HES1, MEF2D, NFIB,
NR2F2, OSR2, PATZ1, RARA, SP2, SP3, SPDEF, SREBF1,
YY1 and TGIF1 (figure 3a). The CRC model proposed by
dbCoRC for GATA3 in breast cancer was further processed
using DisGeNet to test the association of these TFs with
other cancers and other diseases (figure 3b) [93,94]. Usingthis programme and without correction for multiple testing,
strong associations with several cancers were identified.
Each link represents the number of overlapping genes anno-
tated to each term, and size represents the number of genes
annotated to each term. These data highlight the importance
of understanding and comparing TFs across awider spectrum
of cancer cell lines and primary tissue, with the objective of
the discovery of overlapping and non-overlapping functions
and mechanisms.5. Methodologies that facilitate the
understanding of CRCs
Next-generation technologies have allowed shifting from
inter-patient tumour variability to the precise characteriz-
ation of intra-tumour genetic, genomic and transcriptional
heterogeneity via multi-regional bulk tissue NGS. Emerging
single-cell transcriptomics, coupled with NGS, allow novel
strategies for therapeutic response prediction and drug devel-
opment. The regulatory mechanisms that govern the
transcriptome and the expression of these regulatory circuits
are now being investigated using WGS to identify non-
coding mutations and chromatin profile using ChIP-seq
(chromatin immunoprecipitation followed by sequencing),
4-C (circulized chromatin conformation capture), ChIA-PET
(chromatin interaction analysis with paired-end tags) and
ATAC-seq (assay for transposase-accessible chromatin fol-
lowed by sequencing) [95,96]. Understanding regulatory
networks at single-cell resolution has empowered efforts to
decipher cancer heterogeneity, differential resistance to
therapy patterns and hierarchical classification, for instance,
in breast cancer [97]. Here, we briefly elaborate on each
method.
ChIP-seq is a technique allows the detection of TF binding
profiles and histone modifications, including the H3K27ac
marks that signify SEs. The challenge with this technique is
obtaining a highly specific antibody [8].
4C-seq is an update of the chromosome conformation
capture (3C) coupled to sequencing (Hi-C) method that quan-
tifies contact frequencies of DNA based on nuclear proximity,
Table 2. Summary of the CRC network data extracted from dbCoRC database for CRC TFs discussed in this review. CRC TFs discussed in this study were
investigated using dbCoRC database to identify the differential utility of these TFs in CRCs models of other human cancer cell lines and primary tissue. The
example provided for the implication of the TF in other cancer cell line or primary tissue represents one of many examples provided by this database.
CRC TF/
malignancy
other cancer cell lines or
primary tissue
examples of upstream/downstream TFs within the CRC model in
this cell line or primary tissue
PHOX2B/ NB NCI-H82 (SCLC) OTX2, SREBF1, TEAD1, MYC, NHLH1, NR2F6, PHOX2B
GATA3/NB
and T-ALL
ZR-75-1 (breast carcinoma) EHF, FOXA1, GATA3, HES1, MEF2D, NFIB, NR2F2, OSR2, PATZ1, RARA, SP2, SP3, SPDEF,
SREBF1, YY1, TGIF1
SOX2/GBM NCI-H69 (SCLC) BARHL1, DLX1, ETS1, FOXA1, SOX2, FOXG1, INSM1, KLF13, KLF7, MSX2, NR2F1, SP8, TCF4,
TEAD1
MYOD1/RMS RH18 (RMS) ARID3A, FOXL1, GLI1, GLI3, HOXC9, IRF1, MAFK, MYOD1, RARA, RXRA, SMAD3, TBX1,
TEAD3, VDR
MYOG/RMS RD (RMS) ETV4, GLI3, HOXC10, HOXC9, HOXD8, KLF7, MYOD1, MYOG, RUNX1, SMAD3, SOX8, TCF7L2,
ZNF219
MYC/LPS NCI-H82 (SCLC) MYC, NHLH1, NR2F6, OTX2, PHOX2B, SREBF1, TEAD1
RUNX1/LPS
and T-ALL
T20020720 (gastric cancer) EHF, ELF3, ETS2, IRF1, IRF2, KLF13, KLF5, MAFF, MEIS1, NR4A1, PRDM1, RREB1, RXRA,
SMAD3, SOX13, TCF7L2, RUNX1
ERG/prostate COLO320 (colorectal cancer) ASCL2, DBP, ERG, FOXG1, FOXP1, MEIS1, OSR1, SOX5, SP1, TBX2, TEAD1, TFAP4, TFAP2C
PAX5/CLL SU-DHL-6 (diffuse large B-cell
lymphoma)
ARID5B, CUX2, ELF1, MAX, PAX5, SMAD3
ETV6/CLL T2000085 (gastric cancer) BCL6, BHLHE40, ETS1, ETV6, GLIS3, HIVEP2, IKZF1, IRF2, KLF7, MEF2D, MEIS1, NR2F2,
RARA, RREB1, RUNX1, SMAD3, ZBTB16
IRF2/CLL HCC1954 (breast cancer) ELF3, FOXI1, HES1, IKZF2, IRF2, NFIA, PBX1, PITX1, SP3, STAT4, TFAP2A, TP63
ELF1/CLL COLO205 (colorectal cancer) ASCL2, BARX2, BHLHE40, DLX2, EHF, ELF1, ELF3, FOS, FOXB1, HES1, HNF1B, IRF1, IRF8,
KLF5, MYB, PDX1, PITX1, RREB1, RUNX1, RUNX3, SMAD3, SREBF1, TCF7, TCF7L2, TEAD1
KLF13/CLL T2001206 (gastric cancer) BHLHE40, ELF3, ETS1, ETS2, ETV6, HIF1A, IRF1, IRF2, KLF5, KLF13, MEIS1, PRDM1, RREB1,
RUNX1, SMAD3, TCF7L2, TGIF1
FOXP1/CLL COLO320 (colorectal cancer) ASCL2, DBP, ERG, FOXG1, FOXP1, MEIS1, OSR1, SOX5, SP1, TBX2, TEAD1, TFAP2C, TFAP4
NFATC1/CLL HBL1 (diffuse large B-cell
lymphoma)
BACH2, EBF1, ETS1, ETV6, FOXP1, HES1, IKZF1, IRF2, IRF4, IRF8, MAX, MEF2A, MEF2D,
NFATC1, NR3C1, PAX5, POU2F2, RORA, RUNX1, TCF4, TBX15, TFEB
KLF12/CLL COLO741 (colorectal cancer) EGR3, EN2, ETS1, KLF12, NR4A1, NR4A2, PKNOX2, RARA, RREB1, SMAD3, SNAI2, SP1,
SREBF1, TBX2, TEAD1, TGIF1
JUN/CLL MiaPaca2 (pancreatic
adenocarcinoma)






and reveals chromatin folding and configuration patterns
[98]. 4C-seq takes into account domains of contact and
inter-domain contact of a specific genomic site within
genome sequences [99]. The main limitation of 4C is technical
biases due to coverage of cis and trans chromosome inter-
actions and the use of restriction enzymes [100,101]. ChIA-
PET detects chromatin interactions associated with a protein
of interest. This method is unbiased and relies on the premise
that proximal DNA sequences from the same cross-linked
molecular complex may be ligated, offering enhanced resol-
ution and throughput compared with previous techniques
[100]. The limitations of ChIA-PET include the requirement
for substantial starting material due to the sequence of exper-
imental steps. An improved adaptation of this method is
proximity ligation-assisted ChIP-seq (PLAC-seq), which fea-
tures shifting forward of the ligation step. Briefly, in this
method, in situ proximity ligation is performed prior to
lysis of the nuclei, significantly reducing the required inputmaterial and improving the efficacy and accuracy over
ChIA-PET [102]. Another improved method of detecting
chromatin conformation mediated by a protein of interest
that addresses limitations of ChIA-PET is HiChIP. This
method also relies on in situ establishment of DNA contacts
prior to lysis of nuclei. Subsequently, ChIP and on-bead
library generation is carried out followed by paired-end
sequencing, revealing the long-range interactome of the
protein of interest [103]. A significant drawback of HiChIP
is the effect of sequencing depth on the accuracy of detected
interactions. Gryder and colleagues address this drawback by
introducing AqUa-HiChIP [104]. This method circumvents
the limitation of HiChIP by absolute quantification of chro-
matin interactions. Briefly, this method relies on a
previously defined ratio of formalin-fixed nuclei of two
different origins (for instance mouse versus human nuclei).
The nuclei are lysed, and upon incorporation and ligation



























Figure 3. (a) GATA3 is indicated in the CRC model of the ZR-75-1 breast
cancer cell line. CRC model output from dbCoRC for GATA3 in the ZR-75-1
breast cancer cell line involving GATA3 regulation of 15 target TFs (by binding
to their SEs). The circumference of each target TF circle is proportionate to the
number of GATA3 binding sites identified in SEs of the gene encoding this
target TF. (b) Using DisGeNet without multiple testing corrections, the CRC
model TFs in (a) show an association with several cancers and other diseases.
Each link represents the number of overlapping genes annotated to each




10biotin capture and paired-end sequencing are performed
[104]. Human chromatin interactions are then normalized to
those of the mouse genome on the grounds of paired-end
tag counts, allowing more accurate quantification of these
interactions. Alongside the experimental method, this group
also provides a streamlined bioinformatics analysis platform
coupled to this method [104].ATAC-seq assays the transposase accessibility of chroma-
tin coupled with next-generation sequencing. It relies on the
insertion of sequencing linkers by a hyperactive Tn5 transpo-
sase enzyme. Sequencing of the linker attached to reads
reveals regions of chromatin accessibility and offers higher
sensitivity compared with other techniques such as DNAse-
seq. Limitations in streamlined bioinformatics analysis
pipelines may be a challenge with this technique [105].
Finally, single-cell-resolution ATAC-seq can inform areas of
chromatin accessibility and shed light on developmental
processes [106].6. Conclusion
This review summarizes CRC TF members associated with
SEs in a range of liquid and solid cancers. CRC TFs create
and maintain cell-type specific regulatory programmes and
define cell identity, a process that is deregulated in many
cancer subtypes. Specific TFs play important roles in forming
CRC networks in several types of cancer cell lines and pri-
mary tissues, suggesting similar yet divergent mechanisms
and players involved in regulatory processes. Reconstruction
of CRCs in cancer cell lines and tissue, obtained by leveraging
genomic technologies, will facilitate the understanding of
deregulation of biological processes in carcinogenesis and
support the reconstruction of a blueprint pertaining to the
identity of a cancer. Consistent with this, transcriptional
addiction is emerging as an important novel drug vulner-
ability in cancers. Therefore, understanding components of
CRCs, associated proteins and regulators can provide oppor-
tunities for targeting of these components for therapeutic
advantage.
Data accessibility. This article has no additional data.
Authors’ contribution. L.J., L.T., R.M.T. and J.P. collected data and wrote
the paper. J.A.W., G.V.G. and S.D.T. wrote the paper. R.M.T.
designed the figures.
Competing interests. We declare we have no competing interests.
Funding. There was no funding associated with this article.
Acknowledgements. G.V.G. acknowledges support from the NIHR Bir-
mingham ECMC, NIHR Birmingham SRMRC, Nanocommons
Horizon 2020-EU (731032), the NIHR Birmingham Biomedical
Research Centre and the MRC HDR UK (HDRUK/CFC/01), an
initiative funded by UK Research and Innovation, Department of
Health and Social Care (England) and the devolved administrations,
and leading medical research charities. The views expressed in this
publication are those of the authors and not necessarily those of
the NHS, the National Institute for Health Research, the Medical
Research Council or the Department of Health.References1. Pereira JD, Sansom SN, Smith J, Dobenecker MW,
Tarakhovsky A, Livesey FJ. 2010 Ezh2, the histone
methyltransferase of PRC2, regulates the balance
between self-renewal and differentiation in
the cerebral cortex. Proc. Natl Acad. Sci. USA 107,
15 957–15 962. (doi:10.1073/pnas.1002530107)
2. Sansom SN, Griffiths DS, Faedo A, Kleinjan DJ, Ruan
Y, Smith J, van Heyningen V, Rubenstein JL, Livesey
FJ. 2009 The level of the transcription factor Pax6 isessential for controlling the balance between neural
stem cell self-renewal and neurogenesis. PLoS
Genet. 5, e1000511. (doi:10.1371/journal.pgen.
1000511)
3. Tuoc TC, Boretius S, Sansom SN, Pitulescu M, Frahm
J, Livesey FJ, Stoykova A. 2013 Chromatin regulation
by BAF170 controls cerebral cortical size and
thickness. Dev. Cell. 25, 256–269. (doi:10.1016/j.
devcel.2013.04.005)4. Raja DA et al. 2020 Histone variant dictates fate
biasing of neural crest cells to melanocyte lineage.
Development 147, dev182576. (doi:10.1242/dev.
182576)
5. Kuznetsov JN, Aguero TH, Owens DA, Kurtenbach S,
Field MG, Durante MA, Rodriguez DA, King ML,
Harbour JW. 2019 BAP1 regulates epigenetic switch
from pluripotency to differentiation in




11cancers. Sci. Adv. 5, eaax1738. (doi:10.1126/sciadv.
aax1738)
6. Saint-André V, Federation AJ, Lin CY, Abraham BJ,
Reddy J, Lee TI, Bradner JE, Young R. 2016 Models
of human core transcriptional regulatory circuitries.
Genome Res. 26, 385–396. (doi:10.1101/gr.197590.
115)
7. Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham
BJ, Lee TI, Bradner JE, Young RA. 2015 Convergence
of developmental and oncogenic signaling pathways
at transcriptional super-enhancers. Mol. Cell. 58,
362–370. (doi:10.1016/j.molcel.2015.02.014)
8. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V,
Sigova AA, Hoke HA, Young RA. 2013 Super-
enhancers in the control of cell identity and disease.
Cell 155, 934–947. (doi:10.1016/j.cell.2013.09.053)
9. Gryder BE et al. 2019 Histone hyperacetylation
disrupts core gene regulatory architecture in
rhabdomyosarcoma. Nat. Genet. 51, 1714–1722.
(doi:10.1038/s41588-019-0534-4)
10. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin
CY, Kagey MH, Rahl PB, Lee TI, Young RA. 2013
Master transcription factors and mediator establish
super-enhancers at key cell identity genes. Cell 153,
307–319. (doi:10.1016/j.cell.2013.03.035)
11. Chapuy B et al. 2013 Discovery and characterization
of super-enhancer-associated dependencies in
diffuse large B cell lymphoma. Cancer Cell. 24,
777–790. (doi:10.1016/j.ccr.2013.11.003)
12. Boeva V et al. 2017 Heterogeneity of neuroblastoma
cell identity defined by transcriptional circuitries.
Nat. Genet. 49, 1408–1413. (doi:10.1038/ng.3921)
13. Young R. 2011 Control of the embryonic stem cell
state. Cell 144, 940–954. (doi:10.1016/j.cell.2011.
01.032)
14. Boyer LA et al. 2005 Core transcriptional regulatory
circuitry in human embryonic stem cells. Cell 122,
947–956. (doi:10.1016/j.cell.2005.08.020)
15. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc
CR, Bradner JE, Lee TI, Young RA. 2013 Selective
inhibition of tumor oncogenes by disruption of
super-enhancers. Cell 153, 320–334. (doi:10.1016/j.
cell.2013.03.036)
16. Takahashi K, Yamanaka S. 2006 Induction of
pluripotent stem cells from mouse embryonic and
adult fibroblast cultures by defined factors. Cell 126,
663–676. (doi:10.1016/j.cell.2006.07.024)
17. Oldridge DA et al. 2015 Genetic predisposition to
neuroblastoma mediated by a LMO1 super-enhancer
polymorphism. Nature 528, 418. (doi:10.1038/
nature15540)
18. Mansour MR et al. 2014 An oncogenic super-
enhancer formed through somatic mutation of a
noncoding intergenic element. Science 346,
1373–1377. (doi:10.1126/science.1259037)
19. Huang M, Chen Y, Yang M, Guo A, Xu Y, Xu L,
Koeffler HP. 2018 dbCoRC: a database of core
transcriptional regulatory circuitries modeled by
H3K27ac ChIP-seq signals. Nucleic Acids Res. 46,
D71–D77. (doi:10.1093/nar/gkx796)
20. Khan A, Zhang X. 2016 dbSUPER: a database of
super-enhancers in mouse and human genome.Nucleic Acids Res. 44, D164–D171. (doi:10.1093/
nar/gkv1002)
21. Lin CY et al. 2016 Active medulloblastoma
enhancers reveal subgroup-specific cellular origins.
Nature 530, 57–62. (doi:10.1038/nature16546)
22. Gryder BE et al. 2019 Chemical genomics reveals
histone deacetylases are required for core regulatory
transcription. Nat. Commun. 10, 3004. (doi:10.1038/
s41467-019-11046-7)
23. Marris JM. 2010 Recent advances in neuroblastoma.
N. Engl. J. Med. 362, 2202–2211. (doi:10.1056/
NEJMra0804577)
24. van Groningen T et al. 2019 A NOTCH feed-forward
loop drives reprogramming from adrenergic to
mesenchymal state in neuroblastoma. Nat.
Commun. 10, 1530. (doi:10.1038/s41467-019-
09470-w)
25. van Groningen T et al. 2017 Neuroblastoma is
composed of two super-enhancer-associated
differentiation states. Nat. Genet. 49, 1261–1266.
(doi:10.1038/ng.3899)
26. Fryer CJ, Lamar E, Turbachova I, Kintner C, Jones KA.
2002 Mastermind mediates chromatin-specific
transcription and turnover of the Notch enhancer
complex. Genes Dev. 16, 1397–1411. (doi:10.1101/
gad.991602)
27. Koch U, Lehal R, Radtke F. 2013 Stem cells living
with a Notch. Development 140, 689–704. (doi:10.
1242/dev.080614)
28. Durbin AD et al. 2018 Selective gene dependencies
in MYCN-amplified neuroblastoma include the core
transcriptional regulatory circuitry. Nat. Genet. 50,
1240–1246. (doi:10.1038/s41588-018-0191-z)
29. Decaesteker B et al. 2018 TBX2 is a neuroblastoma
core regulatory circuitry component enhancing
MYCN/FOXM1 reactivation of DREAM targets. Nat.
Commun. 9, 4866. (doi:10.1038/s41467-018-
06699-9)
30. Zeid R et al. 2018 Enhancer invasion shapes MYCN-
dependent transcriptional amplification in
neuroblastoma. Nat. Genet. 50, 515–523. (doi:10.
1038/s41588-018-0044-9)
31. Wang L et al. 2019 ASCL1 is a MYCN- and LMO1-
dependent member of the adrenergic
neuroblastoma core regulatory circuitry. Nat.
Commun. 10, 5622. (doi:10.1038/s41467-019-
13515-5)
32. Peng H, Ke XX, Hu R, Yang L, Cui H, Wei Y. 2015
Essential role of GATA3 in regulation of
differentiation and cell proliferation in SK-N-SH
neuroblastoma cells. Mol. Med. Rep. 11, 881–886.
(doi:10.3892/mmr.2014.2809)
33. Hämmerle B, Yañez Y, Palanca S, Cañete A, Burks
DJ, Castel V, de Mora J F. 2013 Targeting
neuroblastoma stem cells with retinoic acid and
proteasome inhibitor. PLoS ONE 8, e76761. (doi:10.
1371/journal.pone.0076761)
34. Zhang Q et al. 2019 Collaborative ISL1/GATA3
interaction in controlling neuroblastoma oncogenic
pathways overlapping with but distinct from
MYCN. Theranostics 9, 86–1000. (doi:10.7150/thno.
30199)35. Soldatov R et al. 2019 Spatiotemporal structure of
cell fate decisions in murine neural crest. Science
364, eaas9536. (doi:10.1126/science.aas9536)
36. Riddick G et al. 2017 A core regulatory circuit in
glioblastoma stem cells links MAPK activation to a
transcriptional program of neural stem cell identity.
Sci. Rep. 7, 43605. (doi:10.1038/srep43605)
37. Bleu M et al. 2019 PAX8 activates metabolic genes
via enhancer elements in renal cell carcinoma. Nat.
Commun. 10, 3739. (doi:10.1038/s41467-019-
11672-1)
38. Chen Y et al. 2019 Bromodomain and extraterminal
proteins foster the core transcriptional regulatory
programs and confer vulnerability in liposarcoma.
Nat. Commun. 10, 1353. (doi:10.1038/s41467-019-
09257-z)
39. Zhang Z et al. 2019 An AR-ERG transcriptional
signature defined by long-range chromatin
interactomes in prostate cancer cells. Genome Res.
29, 223–235. (doi:10.1101/gr.230243.117)
40. Ran L et al. 2015 Combined inhibition of MAP
kinase and KIT signaling synergistically destabilizes
ETV1 and suppresses GIST tumor growth. Cancer
Discov. 5, 304–315. (doi:10.1158/2159-8290.CD-14-
0985)
41. Ott CJ et al. 2018 Enhancer architecture and
essential core regulatory circuitry of chronic
lymphocytic leukemia. Cancer Cell. 34, 982–995.
(doi:10.1016/j.ccell.2018.11.001)
42. Sanda K et al. 2012 Core transcriptional regulatory
circuit controlled by the TAL1 complex in human T
cell acute lymphoblastic leukemia. Cancer Cell. 22,
209–221. (doi:10.1016/j.ccr.2012.06.007)
43. Patel AP et al. 2014 Single-cell RNA-seq highlights
intratumoral heterogeneity in primary glioblastoma.
Science 344, 1396–1401. (doi:10.1126/science.
1254257)
44. Suvà ML et al. 2014 Reconstructing and
reprogramming the tumor-propagating potential of
glioblastoma stem-like cells. Cell 157, 580–594.
(doi:10.1016/j.cell.2014.02.030)
45. Ying M et al. 2011 Regulation of glioblastoma stem
cells by retinoic acid: role for Notch pathway
inhibition. Oncogene 30, 3454–3467. (doi:10.1038/
onc.2011.58)
46. Zhu X, Zhou W, Jin H, Li T. 2018 Brn2 alone is
sufficient to convert astrocytes into neural
progenitors and neurons. Stem Cells Dev. 27,
736–744. (doi:10.1089/scd.2017.0250)
47. Graham V, Khudyakov J, Ellis P, Pevny L. 2003 SOX2
functions to maintain neural progenitor identity.
Neuron 39, 749–765. (doi:10.1016/S0896-
6273(03)00497-5)
48. Ligon KL et al. 2007 Olig2-regulated lineage-
restricted pathway controls replication competence
in neural stem cells and malignant glioma. Neuron
53, 503–517. (doi:10.1016/j.neuron.2007.01.009)
49. Godlewski J et al. 2008 Targeting of the Bmi-1
oncogene/stem cell renewal factor by microRNA-128
inhibits glioma proliferation and self-renewal.





1250. Liu C et al. 2011 Wnt/beta-Catenin pathway in
human glioma: expression pattern and clinical/
prognostic correlations. Clin. Exp. Med. 11,
105–112. (doi:10.1007/s10238-010-0110-9)
51. Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W,
Qiu Y, Xie Q, Ge J. 2012 Notch1 promotes glioma
cell migration and invasion by stimulating β-catenin
and NF-κB signaling via AKT activation. Cancer Sci.
103, 181–190. (doi:10.1111/j.1349-7006.2011.
02154.x)
52. Purow BW et al. 2005 Expression of Notch-1 and its
ligands, Delta-like-1 and Jagged-1, is critical for
glioma cell survival and proliferation. Cancer Res.
65, 2353–2363. (doi:10.1158/0008-5472.CAN-
04-1890)
53. Lee J et al. 2006 Tumor stem cells derived from
glioblastomas cultured in bFGF and EGF more
closely mirror the phenotype and genotype of
primary tumors than do serum-cultured cell lines.
Cancer Cell 9, 391–403. (doi:10.1016/j.ccr.2006.
03.030)
54. Qin S, Liu M, Niu W, Zhan CL. 2011 Dysregulation of
Kruppel-like factor 4 during brain development
leads to hydrocephalus in mice. Proc. Natl Acad. Sci.
USA 108, 21 117–21 121. (doi:10.1073/pnas.
1112351109)
55. Carro MS et al. 2010 The transcriptional network
for mesenchymal transformation of brain
tumours. Nature 463, 318–325. (doi:10.1038/
nature08712)
56. Córdoba Rovira SM, Inarejos Clemente EJ. 2016
Childhood rhabdomyosarcoma. Radiologia 58,
481–490. (doi:10.1016/j.rx.2016.09.003)
57. Morris JP, Yashinskie JJ, Koche R. 2019 α-
Ketoglutarate links p53 to cell fate during tumour
suppression. Nature 573, 595–599. (doi:10.1038/
s41586-019-1577-5)
58. Stewart E et al. 2018 Identification of therapeutic
targets in rhabdomyosarcoma through integrated
genomic, epigenomic, and proteomic analyses.
Cancer Cell 34, 411–426. (doi:10.1016/j.ccell.2018.
07.012)
59. Gryder BE et al. 2017 PAX3-FOXO1 establishes
myogenic super enhancers and confers BET
bromodomain vulnerability. Cancer Discov. 7,
884–899. (doi:10.1158/2159-8290.CD-16-1297)
60. Schmidt K, Glaser G, Wernig A, Wegner M, Rosorius
O. 2003 Sox8 is a specific marker for muscle satellite
cells and inhibits myogenesis. J. Biol. Chem. 278,
29 769–29 775. (doi:10.1074/jbc.M301539200)
61. Weider M, Wegner M. 2017 SoxE factors:
transcriptional regulators of neural differentiation
and nervous system development. Semin. Cell Dev.
Biol. 63, 35–42. (doi:10.1016/j.semcdb.2016.
08.013)
62. Gryder BE et al. 2020 Miswired enhancer logic
drives a cancer of the muscle lineage. iScience 23,
101103. (doi:10.1016/j.isci.2020.101103)
63. Hsieh JJ, Purdue MP, Signoretti S, Swanton C,
Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra
V. 2017 Renal cell carcinoma. Nat. Rev. Dis. Prim. 3,
17009. (doi:10.1038/nrdp.2017.9)64. Kaelin WG. 2007 von Hippel-Lindau Disease. Annu.
Rev. Pathol. Mech. Dis. 2, 145–173. (doi:10.1146/
annurev.pathol.2.010506.092049)
65. Ricketts CJ et al. 2018 The cancer genome atlas
comprehensive molecular characterization of renal
cell carcinoma. Cell Rep. 23, 3698. (doi:10.1016/j.
celrep.2018.06.032)
66. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens
F. 2013 WHO classification of tumours of soft tissue
and bone. Lyon, France: IARC Press.
67. Kanojia D et al. 2015 Genomic landscape of
liposarcoma. Oncotarget. 6, 42 429–42 444. (doi:10.
18632/oncotarget.6464)
68. Jones RL, Fisher C, Al-Muderis O, Judson I. 2005
Differential sensitivity of liposarcoma subtypes to
chemotherapy. Eur. J. Cancer 41, 2853–2860.
(doi:10.1016/j.ejca.2005.07.023)
69. Göransson M, Andersson MK, Forni C, Ståhlberg A,
Andersson C, Olofsson A, Mantovani R, Aman P.
2009 The myxoid liposarcoma FUS-DDIT3 fusion
oncoprotein deregulates nf-kappab target genes by
interaction with NFKBIZ. Oncogene. 28, 270–278.
(doi:10.1038/onc.2008.378)
70. Knight JC, Renwick PJ, Dal Cin P, Van den Berghe H,
Fletcher CD. 1995 Translocation t(12;16)(q13;p11) in
myxoid liposarcoma and round cell liposarcoma:
molecular and cytogenetic analysis. Cancer Res. 55,
24–27.
71. Shi J, Vakoc CR. 2014 The mechanisms behind the
therapeutic activity of BET bromodomain inhibition.
Mol. Cell. 54, 728–736. (doi:10.1016/j.molcel.2014.
05.016)
72. Shen MM, Abate-Shen C. 2010 Molecular genetics
of prostate cancer: new prospects for old challenges.
Genes Dev. 24, 1967–2000. (doi:10.1101/gad.
1965810)
73. Chen Y, Sawyers CL. 2010 Coordinate transcriptional
regulation by ERG and androgen receptor in fusion-
positive prostate cancers. Cancer Cell. 17, 415–416.
(doi:10.1016/j.ccr.2010.04.022)
74. Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng
NY, Cheung E. 2012 A transcriptional repressor co-
regulatory network governing androgen response in
prostate cancers. EMBO J. 31, 2810–2823. (doi:10.
1038/emboj.2012.112)
75. Chi P et al. 2010 etv1 is a lineage survival factor
that cooperates with KIT in gastrointestinal stromal
tumours. Nature 467, 849–853. (doi:10.1038/
nature09409)
76. Hirota S et al. 1998 Gain-of-function mutations of c-
kit in human gastrointestinal stromal tumors.
Science 279, 577–580. (doi:10.1126/science.279.
5350.577)
77. Jones DTW et al. 2012 Dissecting the genomic
complexity underlying medulloblastoma. Nature
488, 100–105. (doi:10.1038/nature11284)
78. Cho YJ et al. 2011 Integrative genomic analysis of
medulloblastoma identifies a molecular subgroup
that drives poor clinical outcome. J. Clin. Oncol. 29,
424–1430. (doi:10.1200/jco.2011.29.4_suppl.424)
79. Northcott PA et al. 2014 Enhancer hijacking
activates GFI1 family oncogenes inmedulloblastoma. Nature 511, 428–434. (doi:10.
1038/nature13379)
80. Hovestadt V et al. 2014 Decoding the regulatory
landscape of medulloblastoma using DNA
methylation sequencing. Nature 510, 537–541.
(doi:10.1038/nature13268)
81. Brown JR et al. 2012 Integrative genomic analysis
implicates gain of PIK3CA at 3q26 and MYC at 8q24
in chronic lymphocytic leukemia. Clin. Cancer Res.
18, 3791–3802. (doi:10.1158/1078-0432.CCR-11-
2342)
82. Landau DA et al. 2013 Evolution and impact of
subclonal mutations in chronic lymphocytic
leukemia. Cell 152, 714–726. (doi:10.1016/j.cell.
2013.01.019)
83. Cozma D et al. 2007 B cell activator PAX5 promotes
lymphomagenesis through stimulation of B cell
receptor signaling. J. Clin. Invest. 117, 2602–2610.
(doi:10.1172/JCI30842)
84. Hunter JE et al. 2016 The NF-κB subunit c-Rel
regulates Bach2 tumour suppressor expression in B-
cell lymphoma. Oncogene 35, 3476–3484. (doi:10.
1038/onc.2015.399)
85. Armstrong SA, Look AT. 2005 Molecular genetics of
acute lymphoblastic leukemia. J. Clin. Oncol. 23,
6306–6315. (doi:10.1200/JCO.2005.05.047)
86. Ramsay RG, Gonda TJ. 2008 MYB function in normal
and cancer cells. Nat. Rev. Cancer 8, 523–534.
(doi:10.1038/nrc2439)
87. Blanke CD et al. 2008 Long-term results from a
randomized phase II trial of standard- versus
higher-dose imatinib mesylate for patients with
unresectable or metastatic gastrointestinal stromal
tumors expressing KIT. J. Clin. Oncol. 26, 620–625.
(doi:10.1200/JCO.2007.13.4403)
88. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G.
2002 Clinical management of gastrointestinal
stromal tumors: before and after STI-571. Hum.
Pathol. 33, 466–477. (doi:10.1053/hupa.2002.
124122)
89. Kwiatkowski N et al. 2014 Targeting transcription
regulation in cancer with a covalent CDK7 inhibitor.
Nature 511, 616–620. (doi:10.1038/nature13393)
90. Ozer HG et al. 2018 BRD4 profiling identifies critical
chronic lymphocytic leukemia oncogenic circuits and
reveals sensitivity to PLX51107, a novel structurally
distinct BET inhibitor. Cancer Discov. 8, 458–477.
(doi:10.1158/2159-8290.CD-17-0902)
91. Bai L et al. 2017 Targeted degradation of BET
proteins in triple-negative breast cancer. Cancer Res.
77, 2476–2487. (doi:10.1158/0008-5472.CAN-16-
2622)
92. Baker EK et al. 2015 BET inhibitors induce apoptosis
through a MYC independent mechanism and
synergise with CDK inhibitors to kill osteosarcoma
cells. Sci. Rep. 5, 10120. (doi:10.1038/srep10120)
93. Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J,
Ronzano F, Centeno E, Sanz F, Furlong LI. 2019 The
DisGeNET knowledge platform for disease genomics:
2019 update. Nucleic Acids Res. 48, D845–D885.
94. Yu G, Wang LG, Yan GR, He QY. 2015 DOSE: an R/




13and enrichment analysis. Bioinformatics 31,
608–609. (doi:10.1093/bioinformatics/btu684)
95. Delaneau O et al. 2019 Chromatin three-
dimensional interactions mediate genetic effects on
gene expression. Science 364, eaat8266. (doi:10.
1126/science.aat8266)
96. Gasperini M et al. 2019 A genome-wide framework
for mapping gene regulation via cellular genetic
screens. Cell 176, 377–390. (doi:10.1016/j.cell.2018.
11.029)
97. Grosselin K et al. 2019 High-throughput single-cell
ChIP-seq identifies heterogeneity of chromatin
states in breast cancer. Nat. Genet. 51, 1060–1066.
(doi:10.1038/s41588-019-0424-9)
98. Lieberman-Aiden E et al. 2009 Comprehensive
mapping of long-range interactions reveals folding
principles of the human genome. Science 326,
289–293. (doi:10.1126/science.1181369)99. Krijger P, Geeven G, Bianchi V, Hilvering C, de Laat
W. 2020 4C-seq from beginning to end: a detailed
protocol for sample preparation and data analysis.
Methods 170, 17–32. (doi:10.1016/j.ymeth.2019.
07.014)
100. Li G, Sun T, Chang H, Cai L, Hong P, Zhou Q. 2019
Chromatin interaction analysis with updated ChIA-
PET tool (V3). Gene 10, 554. (doi:10.3390/
genes10070554)
101. Raviram R, Rocha PP, Bonneau R, Skok JA. 2014
Interpreting 4C-Seq data: how far can we go?
Epigenomics 6, 455–457. (doi:10.2217/epi.14.47)
102. Fang R, Yu M, Li G, Chee S, Liu T, Schmitt AD, Ren
B. 2016 Mapping of long-range chromatin
interactions by proximity ligation-assisted ChIP-seq.
Cell Res. 26, 1345–1348. (doi:10.1038/cr.2016.137)
103. Mumbach MR, Rubin AJ, Flynn RA, Dai C, Khavari
PA, Greenleaf WJ, Chang HY. 2016 HiChIP: efficientand sensitive analysis of protein-directed genome
architecture. Nat. Methods 13, 919–922. (doi:10.
1038/nmeth.3999)
104. Gryder BE, Khan J, Stanton BZ. 2020 Measurement
of differential chromatin interactions with absolute
quantification of architecture (AQuA-HiChIP). Nat.
Protoc. 15, 1209–1236. (doi:10.1038/s41596-019-
0285-9)
105. Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. 2015
ATAC-seq: a method for assaying chromatin
accessibility genome-wide. Curr. Protoc. Mol. Biol.
109, 21.29.1–21.29.9. (doi:10.1002/0471142727.
mb2129s109)
106. Preissl S et al. 2018 Single-nucleus analysis of
accessible chromatin in developing mouse forebrain
reveals cell-type-specific transcriptional regulation.
Nat. Neurosci. 21, 432–439. (doi:10.1038/s41593-
018-0079-3)00121
